JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M908695199 on June 6, 2000

J. Biol. Chem., Vol. 275, Issue 33, 25292-25298, August 18, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/33/25292    most recent
M908695199v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sayer, M. S.
Right arrow Articles by Klinken, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sayer, M. S.
Right arrow Articles by Klinken, S. P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Ectopic Expression of Transcription Factor NF-E2 Alters the Phenotype of Erythroid and Monoblastoid Cells*

Melissa S. SayerDagger §, Peta A. TilbrookDagger §, Angelo SpadacciniDagger §, Evan IngleyDagger §, Mohinder K. SarnaDagger §, James H. WilliamsDagger §, Nancy C. Andrews, and S. Peter KlinkenDagger §||

From the Dagger  Laboratory for Cancer Medicine, Western Australian Institute for Medical Research, Royal Perth Hospital, Perth WA 6000, Australia, the § Department of Biochemistry, University of Western Australia, Nedlands 6907, Australia, and the  Howard Hughes Medical Institute, Children's Hospital, and Harvard Medical School, Boston, Massachusetts 02115

Received for publication, October 26, 1999, and in revised form, May 31, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, regulation of transcription factor NF-E2 was examined in differentiating erythroid and myeloid cells, and the impact of raising NF-E2 concentrations within these cell types was assessed. NF-E2 was expressed in the J2E erythroid cell line, but the levels increased only marginally during erythropoietin-induced differentiation. In contrast, rare myeloid variants of J2E cells did not express NF-E2. Although NF-E2 was present in M1 monoblastoid cells, it was undetectable as these cells matured into macrophages. Compared with erythroid cells, transcription of the NF-E2 gene was reduced, and the half-life of the mRNA was significantly shorter in monocytoid cells. Ectopic expression of NF-E2 had a profound impact upon the J2E cells; morphologically mature erythroid cells spontaneously emerged in culture, but the cells failed to synthesize hemoglobin, even in the presence of erythropoietin. Although proliferation and viability increased in the NF-E2-transfected J2E cells, their responsiveness to erythropoietin was severely diminished. Strikingly, increasing the expression of NF-E2 in M1 cells produced sublines that contained erythroid or immature megakaryocytic cells. Finally, overexpression of NF-E2 in primary hemopoietic progenitors from fetal liver increased erythroid colony formation in the absence of erythropoietin. These data demonstrate that elevated NF-E2 (i) had a dominant effect on the phenotype and maturation of J2E erythroid cells, (ii) was able to reprogram the M1 monocytoid line, and (iii) promoted the development of erythroid colonies by normal progenitors.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Several transcription factors have been shown to play a critical role in the development of various hemopoietic lineages, with different combinations of these regulatory proteins directing lineage fate (1). Increasing evidence is emerging that the concentration of transcription factors influences lineage commitment. Indeed, by manipulating the levels of transcription factors in cell lines, the plasticity of the hemopoietic system has been demonstrated (2, 3). The phenomenon of hemopoietic lineage switching (4) probably occurs because of alterations to the levels of transcription factors.

NF-E2 is a heterodimeric transcription factor that consists of a hemopoietic-restricted subunit (p45NF-E2) and a ubiquitously expressed subunit belonging to the Maf family of proteins (5, 6). NF-E2 is expressed primarily in erythroid cells, but is also found at lower levels in progenitor, megakaryocytic, mast, and granulocytic cells (5). It binds to an extended AP-1-binding site, (T/C)GCTGA(G/C)TCA(T/C) (7), present in the promoters of genes for heme biosynthesis (8-12) and in the locus control region of globin genes (7, 13, 14). Loss of NF-E2 expression in murine erythroleukemia cells results in a drastic reduction in alpha - and beta -globin expression (15, 16). Thus, in vitro studies have implicated NF-E2 as a major regulator of hemoglobin production during erythropoiesis (17).

NF-E2 knockout mice display an unexpectedly mild diserythropoiesis. Alterations to the erythroid compartment are most pronounced in neonates, where anemia, dysmorphic red cells, and decreased hemoglobin content are observed (18). However, these mice die shortly after birth due to a lack of circulating platelets, indicating that NF-E2 plays a key role in megakaryopoiesis (19). While megakaryocytes are present in the NF-E2-/- mice, they have aberrant distribution of demarcation membranes and platelet fields in their cytoplasm (19). Although megakaryocytes in these mice can respond to thrombopoietin, they fail to produce platelets, suggesting that NF-E2 is required in the late stages of megakaryopoiesis (19-21). Recently, Levin et al. (22) demonstrated that NF-E2 is required for megakaryocyte proliferation as well as differentiation. To date, NF-E2 has been shown to bind to the promoter and to regulate the expression of only one megakaryocytic gene, viz. thromboxane synthase (23).

To further examine the effect of NF-E2 in different hemopoietic lineages, we generated J2E erythroid and M1 monoblastoid cell lines that express NF-E2 ectopically. J2E cells are erythropoietin (epo)1-responsive and show enhanced proliferation and viability, morphological maturation, and accumulation of hemoglobin when exposed to the hormone (24-26). However, under adverse conditions, J2E cells have occasionally switched lineage and displayed the phenotype of monocytoid cells (27). In contrast, M1 cells are immature myeloid cells that develop into macrophages in response to interleukin-6 (IL-6) or leukemia inhibitory factor (LIF) (28). Here we show that excess NF-E2 promoted a mature erythroid phenotype in both J2E and M1 cell lines and the appearance of immature megakaryocytes in one clone of the M1 cells. Furthermore, the higher level of NF-E2 in J2E cells interfered with hemoglobin synthesis, proliferation, viability, and responsiveness to epo. Erythroid colony formation by nontransformed progenitors was also enhanced by elevated NF-E2 levels. These data demonstrate that changing the concentration of NF-E2 in hemopoietic cells has a profound effect on their phenotype.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- The J2E (24) and M1 (28) cell lines and the J2E myeloid lines J2E-m1, J2E-m2, J2E-m3, J2E-NR-m1, J2E-NR-m2, and J2E-NR-m3 (27) were maintained in Dulbecco's modified Eagle's medium with 5% fetal calf serum. For differentiation studies, M1 cells were stimulated with either LIF (5 ng/ml) or IL-6 (32 ng/ml), whereas J2E cells were induced with epo (5 units/ml). Cell viability was determined by eosin exclusion (25), and hemoglobin synthesis was determined by benzidine (29) or diaminofluorene (30) staining. Proliferation assays were performed on cells transferred to RPMI 1640 medium (Biosciences, New South Wales, Australia) immediately before the assay. Cultures were then established at 103 cells/100 µl and stimulated with epo for 16 h before being pulsed with 0.5 µCi of [methyl-3H]thymidine (Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom) for 4 h. Cell morphology was examined by cytocentrifuging cells onto glass slides and immersion in Wright's stain. For hemoglobin spectra, cells (5 × 107) were lysed in water for 1 h on ice, and scans were performed between 350 and 700 nm. Expression of the epo receptor was determined by cytocentrifuging cells onto glass slides, fixing in 2.5% paraformaldehyde, and incubating in the presence of an anti-epo receptor polyclonal antibody, followed by a fluorescein isothiocyanate-conjugated anti-rabbit secondary antibody (Amersham Pharmacia Biotech) and examination by immunofluorescence. The rabbit anti-epo receptor antibody was made using the extracellular domain of the epo receptor fused to glutathione S-transferase as the immunizing agent.

Retroviral Infection-- The retroviral vector pRuf(tk)Neo (31) was used to express the entire coding region of p45NF-E2. The packaging cell line PA317 was then transfected with the retroviral construct by calcium phosphate precipitation (32), and supernatants containing amphotropic retroviruses were used to infect J2E and M1 cells. Cells were selected in Geneticin (Sigma) before cloning in methylcellulose as described elsewhere (26). Six to twelve independent colonies were isolated for each construct, and integration of the construct was confirmed by Southern analysis. The NF-E2 retroviral construct was also transfected in Psi 2 cells, and ecotropic virus-containing supernatants were used to infect day 12 fetal liver cells. These cell were then placed in methylcellulose cultures as described previously (33) and counted 7 days later.

Flow Cytometry-- M1 cells (106) were incubated with Mac-1 anti-mouse Ig antibody (34) for 30 min on ice, washed, and then incubated with secondary antibodies conjugated to fluorescein isothiocyanate (Silenus Laboratories, Hawthorn, Victoria, Australia) for 30 min on ice. The cells were washed again before analysis on a Beckman-Coulter Epics XL/MCL flow cytometer. Cells incubated in the absence of primary antibody were analyzed as controls.

Western Blotting-- Protein analyses has been described in detail previously (35-37). Membranes were incubated with antibodies to NF-E2 (5) or to Raf or mitogen-activated protein kinase (MAPK) (SC-133 and SC-154, respectively, Santa Cruz Biotechnology), followed by horseradish peroxidase-conjugated anti-rabbit antibodies (Amersham Pharmacia Biotech), and visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech). Quantitation analysis was performed using NIH Image Version 1.6.1 computer software.

Northern Analyses and Nuclear Run-on Assays-- Total cytoplasmic RNA was isolated by the method of Chomczynski and Sacchi (38) and separated on formaldehyde-agarose gels as described previously (24, 25). After transfer to Hybond N+ nylon membranes (Amersham Pharmacia Biotech), RNA was hybridized to 32P-labeled probes for NF-E2 (5), GATA-1 (39), EKLF (40), beta -major globin (41), or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (42) and then exposed to PhosphorImager screens (Molecular Dynamics, Inc., Sunnyvale, CA). For mRNA stability assays, cells (5 × 105 cells/ml) were incubated with 10 µg/ml actinomycin D (Sigma), and RNA was collected at various time points afterward. For run-on transcription assays, nuclei were prepared from 1 × 108 cells, and the assays were performed using modifications of the methods of Piechaczyk et al. (43) and Linial et al. (44) as we described elsewhere (35). Nylon filters were prepared containing 5 µg of NF-E2 and GAPDH. Typically, 2 × 107 cpm of labeled RNA in 2 ml of hybridization buffer was added to each filter. All quantitation was performed using ImageQuant Version 1.1 software (Molecular Dynamics, Inc.).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

NF-E2 Levels during Erythroid and Myeloid Differentiation-- To monitor changes in NF-E2 levels during erythroid differentiation, J2E cells were stimulated with epo. Untreated J2E cells expressed the transcription factor, and the levels of NF-E2 transcripts and protein increased slightly during epo-induced differentiation (Fig. 1, A and B). Although the rise was modest (20-50%), it was reproducible. These observations are consistent with a marginal increase in NF-E2 transcription determined by nuclear run-on assay (data not shown).


View larger version (41K):
[in this window]
[in a new window]
  		Fig. 1.   Expression of NF-E2 transcripts in J2E erythroid and myeloid cell lines. A, shown are the results from Northern analysis of RNA from J2E cells stimulated with epo (5 units/ml) and probed with NF-E2, followed by GAPDH. B, J2E cells were stimulated with epo (5 units/ml), and lysates (100 µg) were immunoblotted with anti-p45NF-E2 antibodies, followed by anti-p42 MAPK antibodies as a loading control. C, nuclear run-on assay was performed on J2E cells and J2E myeloid cell lines showing transcription of NF-E2 and GAPDH; pGEM acted as a negative control. D, shown are the results from Northern analysis of RNA from J2E cells and myeloid derivatives of J2E cells probed with NF-E2, followed by GAPDH. E, J2E and J2E myeloid cell line lysates (100 µg) were immunoblotted with anti-p45NF-E2 antibodies, followed by anti-p42 MAPK antibodies as a loading control.

Since J2E cells have occasionally generated mutants that have switched lineage and developed a monocytoid phenotype (27), NF-E2 expression was examined in these myeloid variants. Significantly, NF-E2 transcription was down-regulated 20-95% in these myeloid lines (Fig. 1C); moreover, NF-E2 mRNA and protein were detected only in J2E-m1 and J2E-m2 cells, the least mature of the monocytoid variants (Fig. 1, D and E). These results indicated that NF-E2 expression was markedly down-regulated in cells displaying a more differentiated monocytic phenotype. To examine changes in NF-E2 levels during monocytic/macrophage maturation more closely, the M1 monoblastoid cell line was induced to differentiate with either IL-6 or LIF. Although uninduced M1 cells expressed NF-E2, both the transcript and protein disappeared as the cells differentiated (Fig. 2, A and B).


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 2.   NF-E2 expression decreases during M1 differentiation. A, shown are the results from Northern analysis of RNA isolated from M1 cells stimulated with IL-6 (32 ng/ml) or LIF (5 ng/ml) and probed with NF-E2, followed by GAPDH. B, M1 cells were stimulated with IL-6 (32 ng/ml), and lysates (100 µg) were immunoblotted with anti-p45NF-E2 antibodies, followed by anti-p42 MAPK antibodies as a loading control. C, the stability of NF-E2 mRNA in J2E and M1 cells was determined by actinomycin D (10 µg/ml) treatment, mRNA isolation over 4 h, and Northern analysis with NF-E2 and GAPDH probes.

The NF-E2 gene was transcribed in all myeloid variants of J2E cells (Fig. 1C), but little mRNA was detected in most lines; we therefore predicted that the transcript might be less stable in monocytoid cells. To determine whether differences in NF-E2 mRNA stability existed between erythroid and myeloid cells, actinomycin D was added to cultures of J2E and M1 cells, and the decay of NF-E2 mRNA was monitored. Fig. 2C shows that NF-E2 transcripts had a half-life of ~80 min in the J2E erythroid cells, compared with only 25 min in M1 monocytoid cells. This abbreviated half-life did not alter appreciably during M1 maturation (data not shown). Together, the data presented in Figs. 1 and 2 show that NF-E2 levels increased slightly during erythroid differentiation, but declined markedly with monocytic maturation via transcriptional and post-transcriptional means.

Ectopic Expression of NF-E2 in J2E and M1 Cells-- To determine the consequences of raising NF-E2 levels in erythroid and myeloid cells, J2E and M1 cells were infected with a retroviral vector containing the entire coding region of NF-E2; these clones were called JNF and MNF, respectively. Numerous clones were obtained, and those displaying the highest expression are shown in Fig. 3 (A and B). Although the virally encoded NF-E2 RNA was up to four times more abundant than endogenous transcripts, NF-E2 protein content rose moderately, indicating that translation, or polypeptide stability, may play an important role in determining the final protein content. Interestingly, there was no appreciable alteration in endogenous NF-E2 transcripts. Although virally produced NF-E2 RNA was present throughout epo-initiated differentiation of JNF cells, both viral and endogenous NF-E2 transcripts decreased during LIF-induced maturation in the M1 transfectants (Fig. 3C). Since transcription from this retroviral vector continues throughout myeloid maturation,2 this result supports the observation of increased turnover of NF-E2 RNA in monocytic cells (Fig. 2C).


View larger version (47K):
[in this window]
[in a new window]
  		Fig. 3.   Expression of NF-E2 in J2E and M1 cells infected with retroviral NF-E2. A, shown are the results from Northern analysis of RNA isolated from J2E and M1 cells infected with retroviral NF-E2 (JNF and MNF, respectively) and probed with NF-E2 and GAPDH. The positions of the viral and endogenous NF-E2 transcripts are indicated. Levels of NF-E2 mRNA were quantitated relative to GAPDH. Endogenous NF-E2 mRNA levels are represented by black bars, and viral NF-E2 mRNA levels by stippled boxes. B, lysates (100 µg) from JNF and MNF lines were immunoblotted with anti-p45NF-E2 antibodies, followed by anti-p42 MAPK antibodies. Levels of p45NF-E2 were quantitated using NIH Image Version 1.6.1 software and are expressed relative to p42 MAPK levels. C, JNF26 and MNF4 cells were induced with epo (5 units/ml) or LIF (5 ng/ml), respectively; the mRNA was isolated over 4 days; and Northern blots were probed with NF-E2 and GAPDH.

Increased Expression of NF-E2 Promotes Morphological Maturation of J2E Cells in the Absence of Hemoglobin Synthesis-- When stimulated with epo, a significant proportion of J2E cells undergo morphological maturation and synthesize hemoglobin (24-26). An example of epo-induced morphological change is shown in Fig. 4A, where some cells display condensed nuclei on the verge of extrusion, whereas others have the appearance of enucleate reticulocytes. The proportion of cells that retain an immature proerythroblastoid phenotype and those with a more differentiated morphology is summarized in Fig. 4C. Surprisingly, numerous mature erythroid cells and reticulocytes were detected in JNF cells in the absence of epo (Fig. 4, B and C); however, these numbers did not change following epo stimulation (Fig. 4C). Thus, increasing the concentration of NF-E2 in these erythroid cells promoted spontaneous morphological maturation.


View larger version (39K):
[in this window]
[in a new window]
  		Fig. 4.   Enforced expression of NF-E2 in J2E cells promotes morphological maturation. J2E cells stimulated with epo (5 units/ml) for 48 h (A) and unstimulated JNF cells (B) were cytocentrifuged onto glass slides, fixed, and stained using Wright's stain. The arrows indicate the presence of orthochromatic erythroblasts and reticulocytes, and the bar represents 10 µm. In C, J2E and JNF cells are classified according to their stage of morphological maturation.

The other characteristic feature of erythroid terminal differentiation is hemoglobin synthesis. The presence of hemoglobin in parental J2E cells and JNF19 and JNF26 cultures was assessed initially by benzidine staining. Fig. 5A shows that, as anticipated, J2E cells produced more hemoglobin after epo stimulation (24-26). In contrast, the JNF19 and JNF26 cells synthesized negligible amounts of hemoglobin in the absence of epo, and these levels did not rise when the hormone was added to the cultures. To confirm this unexpected observation, hemoglobin levels were ascertained by spectral scans. The data shown in Fig. 5B demonstrate that unstimulated J2E cells contain hemoglobin with absorbance peaks appearing at 413, 540, and 577 nm, whereas significantly reduced levels were detected in JNF19 and JNF26 cells. Therefore, elevating NF-E2 levels in J2E cells enhanced morphological maturation, but suppressed hemoglobin synthesis.


View larger version (15K):
[in this window]
[in a new window]
  		Fig. 5.   Enforced expression of NF-E2 in J2E cells reduces hemoglobin synthesis. A, J2E and JNF cells were stimulated in the absence (white bars) or presence (black bars) of epo (5 units/ml) for 48 h, and differentiation was measured by benzidine staining. B, a spectral scan was performed at 390-600 nm on J2E and JNF cells. The arrows indicate the positions of the oxyhemoglobin peaks. C, the proliferation of J2E and JNF cells was measured by incorporation of [3H]thymidine. D, cell viability was measured by eosin exclusion. Error bars represent S.D. (n = 3).

NF-E2 Accelerates Proliferation-- In addition to morphological changes and hemoglobin synthesis, J2E cells respond to epo with a burst of proliferation and remain more viable under serum-free conditions (24, 25, 37, 45). Therefore, the effect of increasing NF-E2 concentrations on replication rate and cell survival was examined next. Interestingly, raising the levels of NF-E2 in J2E cells increased the incorporation of [3H]thymidine (Fig. 5C) and the rate of cell division (data not shown). Although uptake of labeled thymidine was 3-5-fold greater in JNF cells compared with the parental line, they failed to respond to epo (Fig. 5C). Similarly, cells expressing exogenous NF-E2 remained more viable in the absence of serum, but reacted moderately to the addition of epo (Fig. 5D). Taken together, altering NF-E2 levels in J2E cells had a dramatic impact on their phenotype, as morphological appearance, hemoglobin synthesis, cell division, and viability were all affected by raising the intracellular concentration of NF-E2.

Erythroid Cells Appear in M1 Cultures Expressing Exogenous NF-E2-- The immature M1 monoblastoid cell develops into macrophages following exposure to a number of agents, including IL-6 and LIF (Fig. 6A). Despite their apparent commitment to the monocytic pathway, introduction of GATA-1 has been shown to induce the appearance of erythroid and megakaryocytic cells in these cultures (2). Similarly, Fig. 6A shows that increased NF-E2 levels in M1 cells promoted the emergence of erythroid cells in two of three sublines. Both MNF4 and MNF11 cultures contained up to 5% erythroid cells, varying from proerythroblast to orthochromatic erythroblasts and reticulocytes. These cells were also present in cultures exposed to LIF, although their proportion did not change (Fig. 6A). A number of hemoglobin-producing cells (3-7%) were detected in these cultures (Fig. 6B), and surface epo receptors were identified by immunofluorescence (Fig. 6C). In contrast with the MNF4 and MNF11 lines, the MNF12 clone contained some very large cells that had the appearance of megakaryocytic precursors (Fig. 6A). However, these cells did not contain acetylcholinesterase (data not shown) and disappeared from culture after the addition of LIF. These data demonstrate that, like GATA-1 (2), NF-E2 can force M1 cells to alter their appearance and to display an erythroid or immature megakaryocytic phenotype.


View larger version (39K):
[in this window]
[in a new window]
  		Fig. 6.   Enforced expression of NF-E2 in M1 cells promotes an erythroid or megakaryoblastoid morphology. A, M1 or MNF cells, unstimulated or stimulated with LIF (5 ng/ml) for 48 h, were cytocentrifuged onto glass slides, fixed, and stained using Wright's stain. The arrows indicate the presence of polychromatic erythroblasts, orthochromatic erythroblasts, and reticulocytes. The bar represents 10 µm. B, unstimulated MNF cells were stained with diaminofluorene to detect hemoglobin. Note the dark staining in the cells marked by arrows, indicating hemoglobin production. C, MNF cells were cytocentrifuged onto glass slides and fixed, and the presence of the epo receptor was detected by immunofluorescence on cells indicated by the arrows.

M1 cells have also been transfected with SCL, another transcription factor important for erythroid cells (46). Although these transfectants did not display any erythroid features, macrophage differentiation was impeded. To examine whether NF-E2 also inhibited the maturation of M1 cells, cultures were exposed to LIF and monitored for the expression of Mac-1, a macrophage surface marker. Fig. 7A shows that, unlike SCL (46), NF-E2 did not interfere with macrophage maturation. Similar results were obtained at all time points and concentrations of LIF examined (data not shown). The difference between the effects of these two transcription factors may be due, in part, to the degradation of NF-E2 as M1 cells mature (Fig. 3C).


View larger version (35K):
[in this window]
[in a new window]
  		Fig. 7.   Enforced expression of NF-E2 in M1 cells does not influence myeloid cell-surface marker expression or induce expression of erythroid-restricted transcripts. A, expression of the mature myeloid cell-surface marker Mac-1 was determined by flow cytometry on M1 or MNF cells with or without LIF (5 ng/ml) for 96 h. The percentage of cells expressing Mac-1 is indicated. B, shown are the results from Northern analysis of RNA isolated from J2E, M1, and MNF cells probed with NF-E2, GATA-1, EKLF, beta -globin, and GAPDH. The positions of the viral and endogenous NF-E2 transcripts are indicated.

To examine the effect of ectopic NF-E2 expression on other erythroid-restricted transcription factors, Northern blots were probed for the presence of GATA-1 and EKLF mRNAs. Fig. 7B shows that elevated NF-E2 did not induce expression of GATA-1 or EKLF. It is possible that NF-E2 was able to impose an erythroid phenotype on M1 cells without an obvious increase in GATA-1 and EKLF; however, it is likely that subtle changes occurred to GATA-1 and EKLF that were not detected by Northern blotting of total RNA.

NF-E2 Increases Erythroid Colony Formation-- Having observed noticeable effects of exogenous NF-E2 expression in cell lines, the consequences of NF-E2 overexpression were examined in primary hemopoietic progenitors. To this end, fetal liver cells were infected with a NF-E2 retrovirus, and colony formation was enumerated 7 days later. Significantly, a 3-4-fold increase in burst-forming units-erythroid (BFU-E) was detected in cultures expressing NF-E2 ectopically (Fig. 8). These colonies were pale and appeared to contain less hemoglobin than controls. Despite the rise in BFU-E with NF-E2, there was no increase in colony formation after treatment with epo. In contrast, exposure to the NF-E2 retrovirus reduced the number of myeloid colonies slightly. These data are consistent with the effects of NF-E2 overexpression in J2E cells (Figs. 4 and 5) and demonstrate that normal erythroid progenitors in particular are influenced by the concentration of NF-E2.


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 8.   NF-E2 overexpression increases BFU-E. Fetal liver cells were infected with an NF-E2-expressing retrovirus and placed in methylcellulose in the presence or absence of epo (5 units/ml) before colony numbers were determined 7 days later. BFU-E were determined by colony morphology and benzidine staining. Myeloid colonies included granulocyte, macrophage, and mixed colonies that were not benzidine-positive. Error bars represent S.D. (n = 6).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we have demonstrated that ectopic expression of NF-E2 had a profound effect on erythroid and monoblastoid cells. In the J2E erythroid cell line, this was manifest by markedly increased proliferation rates, spontaneous morphological maturation, suppressed hemoglobin synthesis, and enhanced viability. Responsiveness to epo was also greatly diminished. These effects in J2E cells are compatible with increased epo-independent BFU-E generated by overexpression of NF-E2 in primary erythroid progenitors. In contrast, enforced NF-E2 expression resulted in the appearance of erythroid or megakaryoblast-like cells in the M1 monoblastoid cultures.

The effect of exogenous NF-E2 on J2E cells is remarkably similar to the effects of overexpressing GATA-1 in murine erythroleukemia cells (47). In both cases, cell division was promoted, at the expense of hemoglobin production. Since NF-E2 has been implicated in the regulation of globin gene transcription in vitro (15, 16) and neonatal NF-E2-/- mice are anemic due to reduced hemoglobin content (18), the inhibition of hemoglobin production in J2E cells due to excess NF-E2 was unexpected. It is possible that by altering the NF-E2 concentration in the cells, albeit modestly (Fig. 3), the equilibrium with other transcription factors has been modified. NF-E2 is known to heterodimerize with members of the Maf family (6) and to bind the thyroid hormone receptor (48). The severe biological consequences of changing NF-E2 concentration in these cells may be due to disruption of these nuclear complexes.

An interesting aspect of this study involved the uncoupling of cytological changes from hemoglobin production in J2E cells. Here, excess NF-E2 promoted spontaneous morphological maturation, without concomitant hemoglobin synthesis, suggesting that two processes regulated coordinately during erythroid terminal differentiation can be dissected. These observations support previous data in EKLF null mice, in which mature red blood cells lacking hemoglobin are produced (49, 50). In addition, down-regulation of EKLF in J2E cells does not prevent reticulocyte formation in the absence of hemoglobin production (51). Significantly, NF-E2-/- mice contain dysmorphic red cells, particularly in neonates (18); moreover, numerous defective red cell fragments are present in NF-E2-/- mice (22). These results suggest that NF-E2 may be an important determinant in the development of morphologically mature erythroid cells.

The expression pattern of NF-E2 during J2E cell differentiation is consistent with several other models of erythropoiesis. Labbaye et al. (52) reported that NF-E2 is expressed throughout the development of normal erythroid cells, and NF-E2 levels remain elevated in chemically induced murine erythroleukemia and K562 cells (53, 54). Similarly, EKLF levels are consistently raised during epo-induced differentiation of J2E cells (51), whereas GATA-1 levels decrease late in the maturation process (36). The down-regulation of NF-E2 in myeloid variants of J2E cells as well as in differentiating M1 cells agrees with the lack of NF-E2 in normal myeloid cells (52). The suppression of NF-E2 in myeloid cells was due not only to reduced transcription of the gene, but also to increased turnover of the transcripts (Figs. 1 and 2). The reduction in virally generated NF-E2 in maturing M1 cells suggests that some instability elements may exist within the coding region of the mRNA, as has been described for other transcripts such as c-fos (55). However, NF-E2 levels did not decrease when J2E cells developed an immature monocytoid appearance due to the introduction of the hemopoietic lineage switch gene HLS7 (33), which is homologous to the novel human oncogene MLF1 (56).

The emergence of erythroid cells in M1 cultures expressing NF-E2 is significant. Clearly, this transcription factor is turned off during monocytic terminal differentiation (Fig. 2), and ectopic expression has generated clones containing erythroid cells. This observation is similar to the introduction of GATA-1 into M1 cells, resulting in the appearance of cells with an erythroid phenotype (2). The presence of cells resembling megakaryoblasts in one clone of M1 cells expressing exogenous NF-E2 is also comparable with the data of Yamaguchi et al. (2) and is consistent with the crucial role of NF-E2 in megakaryocyte development identified in knockout mice (19). These experiments demonstrate M1 cells have a propensity to generate erythroid and megakaryocytic cells if the transcription factor ratio is altered. The reprogramming of M1 cells by NF-E2 is also similar to the ability of GATA-1 to generate erythroblasts, thromboblasts, and eosinophils from transformed myelomonocytic cells (3).

Overexpression of NF-E2 in primary hemopoietic cells substantially increased BFU-E numbers in the absence of epo, but only slightly reduced myeloid colony formation. These data reflect the impact of exogenous NF-E2 on J2E and M1 cell lines and suggest that increased NF-E2 expression favors erythroid development over myeloid maturation in agreement with the role of NF-E2 in erythroid gene regulation (8-17). Although elevated NF-E2 promoted BFU-E formation, the colonies appeared pale and poorly hemoglobinized, which was similar to the increased proliferation and reduced hemoglobin synthesis observed in JNF cells. Thus, as seen with the NF-E2-/- mice (18, 22), the correct concentration of NF-E2 is essential for complete development of red blood cells. It is possible that rapid degradation of NF-E2 transcripts in myeloid cells (Fig. 2) may have prevented a more significant effect on colony formation in that lineage.

Taken together, the information presented here on ectopic NF-E2 expression in normal and immortalized cells highlights the importance of transcription factor concentrations during the development and terminal differentiation of hemopoietic cells (1). Interference with this delicate balance can have dramatic ramifications for the production of fully functional blood cells.

    ACKNOWLEDGEMENTS

Recombinant human epo (Eprex) was a generous gift from Drs. J. Adams and J. Patava (Jansen-Cilag, Sidney, Australia). We thank Jennifer Beaumont for excellent technical assistance.

    FOOTNOTES

* This work was supported by Grants 99-0596 and 11-0298 from the Natiional Health and Medical Research Council and by grants from the Medical Research Foundation of Royal Perth Hospital and the Cancer Foundation of Western Australia (to P. A. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Western Australian Inst. for Medical Research, Level 6, MRF Bldg., Rear 50 Murray St., Perth WA 6000, Australia. Tel.: 61-8-92240334; Fax: 61-8-92240322; E-mail: pklinken@cyllene.uwa.edu.au.

Published, JBC Papers in Press, June 6, 2000, DOI 10.1074/jbc.M908695199

2 T. J. Gonda, personal communication.

    ABBREVIATIONS

The abbreviations used are: epo, erythropoietin; IL-6, interleukin-6; LIF, leukemia inhibitory factor; MAPK, mitogen-activated protein kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; BFU-E, burst-forming units-erythroid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Orkin, S. H. (1995) J. Biol. Chem. 270, 4955-4958
2. Yamaguchi, Y., Zon, L. I., Ackerman, S. J., Yamamoto, M., and Suda, T. (1998) Blood 91, 450-457
3. Kulessa, H., Frampton, J., and Graf, T. (1995) Genes Dev. 9, 1250-1262
4. Klinken, S. P., Alexander, W. S., and Adams, J. M. (1988) Cell 53, 857-867
5. Andrews, N. C., Erdjument-Bromage, H., Davidson, M. B., Tempst, P., and Orkin, S. H. (1993) Nature 362, 722-728
6. Andrews, N. C., Kotkow, K. J., Ney, P. A., Erdjument-Btomage, H., Tempst, P., and Orkin, S. H. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 11488-11492
7. Ney, P. A., Sorrentino, B. P., Lowery, C. H., and Nienhuis, A. W. (1990) Nucleic Acids Res. 18, 6011-6017
8. Mignotte, V., Wall, L., deBoer, E., Grosveld, F., and Romeo, P. H. (1989) Nucleic Acids Res. 17, 37-54
9. Mignotte, V., Eleouet, J. F., Raich, N., and Romeo, P. H. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 6548-6552
10. Romeo, P. H., Prandini, M. H., Jiulin, V., Mignotte, V., Prenant, M., Vainchecker, W., Marguerie, G., and Uzan, G. (1990) Nature 344, 447-449
11. Cox, T. C., Bawden, M. J., Martin, A., and May, B. K. (1991) EMBO J. 10, 1891-1902
12. Taketani, S., Inazawa, J., Nakahashi, Y., Abe, T., and Tokunaga, R. (1992) Eur. J. Biochem. 205, 217-222
13. Higgs, D. R., Wood, W. G., Jarman, A. P., Sharpe, J., Lida, J., Pretorious, I.-M., and Ayyub, H. (1990) Genes Dev. 4, 1588-1601
14. Jarman, A. P., Wood, W. G., Sharpe, J. A., Gourdon, G., Ayyub, H., and Higgs, D. R. (1991) Mol. Cell. Biol. 11, 4679-4689
15. Lu, S. J., Rowan, S., Ban, M. R., and Ben-David, Y. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8398-8402
16. Kotkow, K. J., and Orkin, S. H. (1995) Mol. Cell. Biol. 15, 4640-4647
17. Andrews, N. C. (1998) Int. J. Biochem. Cell Biol. 30, 429-432
18. Shivdasani, R. A., and Orkin, S. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8690-8694
19. Shivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W., Hunt, P., Saris, C. J. M., and Orkin, S. H. (1995) Cell 81, 695-704
20. Shivdasani, R. A. (1996) Stem Cells 14, 112-115
21. Shivdasani, R. A., Fielder, P., Keller, G.-A., Orkin, S. H., and de Sauvage, F. J. (1997) Blood 90, 1821-1827
22. Levin, J., Peng, J. P., Baker, G. R., Villeval, J. L., Lecine, P., Burstein, S. A., and Shivdasani, R. A. (1999) Blood 94, 3037-3047
23. Deveaux, S., Cohen-Kaminsky, S., Shivdasani, R. A., Andrews, N. C., Filipe, A., Kuzniak, I., Orkin, S. H., Romeo, P. H., and Mignotte, V. (1997) EMBO J. 16, 5654-5661
24. Klinken, S. P., Nicola, N. A., and Johnson, G. R. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8506-8510
25. Busfield, S. J., and Klinken, S. P. (1992) Blood 80, 412-419
26. Tilbrook, P. A., Ingley, E., Williams, J. H., Hibbs, M. L., and Klinken, S. P. (1997) EMBO J. 16, 1610-1619
27. Keil, U., Busfield, S. J., Farr, T. J., Papadimitriou, J., Green, A. R., Begley, C. G., and Klinken, S. P. (1995) Cell Growth Differ. 6, 439-448
28. Lotem, J., Shabo, Y., and Sachs, L. (1989) Leukemia (Baltimore) 3, 804-807
29. Cooper, M. C., Levy, J., Cantor, L. N., Marks, P. A., and Rifkind, P. A. (1974) Proc. Natl. Acad. Sci. U. S. A. 71, 1677-1680
30. Callus, B. A., Busfield, S. J., and Klinken, S. P. (1995) Hemoglobin 19, 7-19
31. Rayner, J. R., and Gonda, T. J. (1994) Mol. Cell. Biol. 14, 880-887
32. Chen, C., and Okayama, H. (1987) Mol. Cell. Biol. 7, 2745-2752
33. Williams, J. H., Daly, L. N., Ingley, E., Beaumont, J. G., Tilbrook, P. A., Lalonde, J. P., Stillitano, J. P., and Klinken, S. P. (1999) EMBO J. 18, 5559-5566
34. Springer, T., Galfre, G., Secher, D. S., and Milstein, C. (1979) Eur. J. Immunol. 9, 301-306
35. Busfield, S. J., Chappell, D. S., Jennings, G., Trengrove, N. J., Riches, K. J., Callus, B. A., Tilbrook, P. A., and Klinken, S. P. (1995) Cell Growth Differ. 6, 429-437
36. Busfield, S. J., Spadaccini, A., Riches, K. J., Tilbrook, P. A., and Klinken, S. P. (1995) Eur. J. Biochem. 230, 475-480
37. Tilbrook, P. A., Bittorf, T., Busfield, S. J., Chappell, D., and Klinken, S. P. (1996) J. Biol. Chem. 271, 3453-3459
38. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159
39. Tsai, S., Martin, D. I. K., Zon, L. I., D'Andrea, A. D., Wong, G. G., and Orkin, S. H. (1989) Nature 339, 446-451
40. Miller, I. J., and Bieker, J. J. (1993) Mol. Cell. Biol. 13, 2776-2786
41. Hofer, E., and Darnell, J. E. (1981) Cell 23, 585-593
42. Piechaczyk, M., Blanchard, J., Martin, L., Dani, C., Panabries, F., El Sabrouty, S., and Jeanteur, P. (1984) Nucleic Acids Res. 12, 6951-6963
43. Piechaczyk, K., Yang, J. Q., Blamchard, J. H., Jeanteur, P., and Marcu, K. (1985) Cell 42, 589-597
44. Linial, G., Gunderson, N., and Groudine, M. (1985) Science 230, 1126-1132
45. Chappell, D., Tilbrook, P. A., Bittorf, T., Colley, S. M., Meyer, G. T., and Klinken, S. P. (1997) Cell Death Differ. 4, 103-113
46. Tanigawa, T., Nicola, N., McArthur, G. A., Strasser, A., and Begley, C. G. (1995) Blood 85, 379-390
47. Whyatt, D. J., Karis, A., Harkes, I. C., Verkerk, A., Gillemans, N., Elefanty, A. G., Vairo, G., Ploemacher, R., Grosveld, F., and Philipsen, S. (1997) Genes Funct. 1, 11-24
48. Cheng, X., Reginato, M. J., Andrews, N. C., and Lazar, M. A. (1997) Mol. Cell. Biol. 17, 1407-1416
49. Perkins, A. C., Sharpe, A. H., and Orkin, S. H. (1995) Nature 375, 318-322
50. Neuz, B., Mikalovich, D., Bygrave, A., Ploemacher, R., and Grosveld, F. (1995) Nature 375, 316-318
51. Spadaccini, A., Tilbrook, P. A., Sarna, M. K., Crossley, M., Bieker, J. J., and Klinken, S. P. (1998) J. Biol. Chem. 273, 23793-23798
52. Labbaye, C., Valtieri, M., Barberi, T., Meccia, E., Masella, B., Pelosi, E., Condorelli, G. L., Testa, U., and Peschle, C. (1995) J. Clin. Invest. 95, 2346-2358
53. Nagai, T., Igarashi, K., Akasake, J., Furuyama, K., Fujita, H., Hyashi, N., Yamamoto, M., and Sassa, S. (1998) J. Biol. Chem. 273, 5358-5365
54. Chenais, B., Molle, I., Trentasaux, C., and Jeannesson, P. (1997) Leukemia (Baltimore) 11, 1575-1579
55. Chen, C. Y., You, Y., and Shyu, A. B. (1992) Mol. Cell. Biol. 12, 5748-5757
56. Yoneda-Kato, N., Look, A. T., Kirstein, M. N., Valentine, M. B., Raimondi, S. C., Cohen, K. J., Caroll, A. J., and Morris, S. W. (1996) Oncogene 12, 265-175

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
P. J. Campbell and A. R. Green
The Myeloproliferative Disorders
N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-P. Lalonde, R. Lim, E. Ingley, P. A. Tilbrook, M. J. Thompson, R. McCulloch, J. G Beaumont, C. Wicking, H. J. Eyre, G. R. Sutherland, et al.
HLS5, a Novel RBCC (Ring Finger, B Box, Coiled-coil) Family Member Isolated from a Hemopoietic Lineage Switch, Is a Candidate Tumor Suppressor
J. Biol. Chem., February 27, 2004; 279(9): 8181 - 8189.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-J. Liu, S.-C. Hou, and C.-K. J. Shen
Erythroid Gene Suppression by NF-{kappa}B
J. Biol. Chem., May 23, 2003; 278(21): 19534 - 19540.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
S. J. Pratt, A. Drejer, H. Foott, B. Barut, A. Brownlie, J. Postlethwait, Y. Kato, M. Yamamoto, and L. I. Zon
Isolation and characterization of zebrafish NFE2
Physiol Genomics, October 29, 2002; 11(2): 91 - 98.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/33/25292    most recent
M908695199v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sayer, M. S.
Right arrow Articles by Klinken, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sayer, M. S.
Right arrow Articles by Klinken, S. P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.